Resverlogix logo

RVX - Resverlogix Share Price

C$0.77 0.0  1.3%

Last Trade - 07/08/20

Sector
Healthcare
Size
Small Cap
Market Cap £93.7m
Enterprise Value £144.1m
Revenue £n/a
Position in Universe 566th / 2679
Bullish
Bearish
Unlock RVX Revenue
Momentum
Relative Strength (%)
1m -4.86%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -74.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Apr 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 31 January 2020, Resverlogix Corp. revenues was not reported. Net income totaled $109.3M vs. loss of $102.1M. Net income reflects Gain) loss on change in fair value of ro increase from $42.7M (expense) to $84.4M (income), FV Adjustments of Financial Investments increase from $26.8M (expense) to $48.8M (income), research and development, balancing decrease of 39% to $13.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

RVX Revenue Unlock RVX Revenue

Net Income

RVX Net Income Unlock RVX Revenue

Normalised EPS

RVX Normalised EPS Unlock RVX Revenue

PE Ratio Range

RVX PE Ratio Range Unlock RVX Revenue

Dividend Yield Range

RVX Dividend Yield Range Unlock RVX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
RVX EPS Forecasts Unlock RVX Revenue
Profile Summary

Resverlogix Corp is Canada-based clinical-stage biotechnology company. The Company is developing apabetalone (RVX-208), a molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, dialysis, Alzheimer's disease, Fabry disease, other orphan diseases, and peripheral artery disease. Apabetalone is being studied in a Phase III trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).

Directors
Last Annual April 30th, 2019
Last Interim January 31st, 2020
Incorporated February 7, 2005
Public Since October 12, 2001
No. of Shareholders: n/a
No. of Employees: 28
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Toronto Stock Exchange
Shares in Issue 212,557,074
Free Float (0.0%)
Eligible for
ISAs
SIPPs
RVX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for RVX
Upcoming Events for RVX
Frequently Asked Questions for Resverlogix
What is the Resverlogix share price?

As of 07/08/20, shares in Resverlogix are trading at C$0.77, giving the company a market capitalisation of £93.7m. This share price information is delayed by 15 minutes.

How has the Resverlogix share price performed this year?

Shares in Resverlogix are currently trading at C$0.77 and the price has moved by -71.79% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Resverlogix price has moved by -72.2% over the past year.

What are the analyst and broker recommendations for Resverlogix?

Of the analysts with advisory recommendations for Resverlogix, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Resverlogix is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Resverlogix next release its financial results?

Resverlogix is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-01-31
What is the Resverlogix dividend yield?

Resverlogix does not currently pay a dividend.

Does Resverlogix pay a dividend?

Resverlogix does not currently pay a dividend.

When does Resverlogix next pay dividends?

Resverlogix does not currently pay a dividend.

How do I buy Resverlogix shares?

To buy shares in Resverlogix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Resverlogix?

Shares in Resverlogix are currently trading at C$0.77, giving the company a market capitalisation of £93.7m.

Where are Resverlogix shares listed? Where are Resverlogix shares listed?

Here are the trading details for Resverlogix:

Country of listing: Canada
Exchange: TOR
Ticker Symbol: RVX
What kind of share is Resverlogix?

Based on an overall assessment of its quality, value and momentum, Resverlogix is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Resverlogix share price forecast 2020?

Shares in Resverlogix are currently priced at C$0.77. At that level they are trading at 1.24% discount to the analyst consensus target price of 0.00.

Analysts covering Resverlogix currently have a consensus Earnings Per Share (EPS) forecast of -0.22 for the next financial year.

How can I tell whether the Resverlogix share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Resverlogix. Over the past six months, the relative strength of its shares against the market has been -38.51%. At the current price of C$0.77, shares in Resverlogix are trading at -26.44% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Resverlogix PE Ratio?

The Resverlogix PE ratio based on its reported earnings over the past 12 months is 3.04. The shares are currently trading at C$0.77.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Resverlogix?

Resverlogix's management team is headed by:

Donald McCaffrey - CHM
Jan Johansson - SVP
Kelly McNeill - IND
Kenneth Lebioda - SVP
Norman Wong - CSO
A. Brad Cann - CFO
Kenneth Zuerblis - IND
Eldon Smith - LED
Michael Sweeney - SVP
Norma Biln - IND
Shawn Lu - DRC
Dicky To - DRC
Ewelina Kulikowski - SVP
Who are the major shareholders of Resverlogix?

Here are the top five shareholders of Resverlogix based on the size of their shareholding:

Shenzhen Hepalink Pharmaceutical Group Co Ltd Corporation
Percentage owned: 38.44% (81.7m shares)
Eastern Capital, Ltd. Corporation
Percentage owned: 13.04% (27.7m shares)
McCaffrey (Donald J) Individual Investor
Percentage owned: 2.2% (4.68m shares)
Zuerblis (Kenneth J) Individual Investor
Percentage owned: 0.05% (107k shares)
McNeill (Kelly) Individual Investor
Percentage owned: 0.05% (105k shares)
Similar to RVX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.